Gap junctions mediate communication between adjacent cells in almost all tissues. Gap junctions are composed of arrays of channel-forming integral membrane proteins, termed connexins (for review, see Refs. 1 and 2). The connexin proteins contain four transmembrane domains with the amino-and COOH-terminal regions located intracellularly. 1 is the most widespread and best studied member of the connexin family, with much attention being focused on its regulation by physiological and pathophysiological stimuli. Cx43-based gap junctional communication (GJC) is transiently inhibited by certain growth factors (1, (3) (4) (5) (6) and permanently reduced or disrupted in most cancer cells and in v-Src-transformed fibroblasts (1, (7) (8) (9) (10) (11) . The COOH-terminal tail of Cx43 contains several serine/threonine and tyrosine phosphorylation sites that are thought to be important for regulating the opening and closure ("gating") of Cx43-based channels (1), but little is still known about how phosphorylation of Cx43 may be linked to the regulation of GJC.
We have reported that Cx43-based GJC in normal fibroblasts is rapidly inhibited after activation of certain G protein-coupled receptors, such as those for lysophosphatidic acid (LPA), endothelin, and thrombin (5) . We found that agonist-induced gap junction closure is independent of classic second messengers, such as calcium and cyclic nucleotides, and does not require the mitogen-activated protein kinase cascade. Instead, gap junction closure was prevented by tyrosine kinase inhibitors, by dominant-negative c-Src, and in c-Src-deficient cells (5) . It thus appears that the c-Src tyrosine kinase is required for disruption of Cx43-based GJC by these G protein-coupled receptor agonists. Although agonist-induced tyrosine phosphorylation of Cx43 could not be detected (5) , the possibility remains that active c-Src may directly interact with Cx43 by analogy of what has been reported for oncogenic v-Src, whose effects on Cx43 and Cx43-based GJC have been investigated extensively (1, (7) (8) (9) (10) (11) (12) (13) . Residue Tyr 265 in the COOH-terminal tail of Cx43 has been implicated as a major target for the v-Src kinase, but uncertainty exists as to the relevance of Tyr 265 phosphorylation in channel gating (12, 13) . In Xenopus oocyte pairs, v-Srcmediated closure of Cx43-based gap junctions was shown to be critically dependent on residue Tyr 265 , since mutation of Tyr 265 in Cx43 prevented gap junction closure (12) . In contrast, more recent experiments using the Xenopus system have suggested that v-Src-induced inhibition of Cx43-based GJC occurs via a pathway that is independent of the Tyr 265 site but seems to require serine phosphorylation sites for mitogen-activated protein kinase (13) . The reason for the discrepancy between both studies is unclear. While the action of oncogenic v-Src on Cx43 has been examined in considerable detail, it remains unknown whether endogenous wild-type c-Src can act similarly on Cx43. Overexpressed c-Src has long been known to mimic v-Src in inhibiting GJC in 3T3 cells (14) . However, where tested, an association between wild-type c-Src and Cx43 in vivo could not be detected (11) .
In the present study we have examined the possible interaction between c-Src and Cx43, both in vitro and in transfected cells. We find that residue Tyr 265 in the COOH-terminal tail of Cx43 is phosphorylated by active c-Src and, furthermore, that Cx43 and active c-Src can be coprecipitated, whereas kinasedead c-Src fails to stably interact with Cx43. Tyrosine phosphorylation and coprecipitation of Cx43 are abolished after mutation of residue Cx43 Tyr 265 . The communication-defective phenotype can be bypassed after introduction of mutant versions of Cx43 that cannot be tyrosine-phosphorylated on Tyr 265 . We conclude that activated c-Src phosphorylates the C-terminal tail of Cx43 on residue Tyr 265 , resulting in a stable interaction between both proteins that contributes to the inhibition of GJC by extracellular agonists. * This work was supported by the Dutch Cancer Society. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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, and c-Src in pMT2 were kindly provided by S. Courtneidge (Sugen, Inc., Redwood City, CA). Myc epitope-tagged fulllength Cx43 and Cx43⌬263 in pCDNA3 (Invitrogen) were constructed as described previously (15) . The Cx43Y265F and Cx43Y267F mutations were introduced by site-directed mutagenesis using 5Ј oligonucleotides (5Ј TGC GGA TCC CCA AAA TTC GCC TAC TTC AAT GGC T 3Ј and 5Ј TGC GGA TCC CCA AAA TAC GCC TTC TTC AAT GGC TGC TCC T 3Ј, respectively) and the 3Ј oligonucleotide (5Ј GGG GCG-GCCGC C AAT CTC CAG GTC ATC AG 3Ј). Polymerase chain reaction was performed according to standard procedures, using rat Cx43 cDNA as template. Polymerase chain reaction products were isolated from gel and BamHI/NotI ligated into Cx43⌬263Myc, in which a BamHI site was introduced in the nucleotides encoding amino acids 261 and 262 (silent mutation). Mutations were verified by sequencing. To construct GSTCx43CT, the COOH-terminal tail of Cx43 was isolated from pMD4Cx43CT (15) with SalI/EcoRI and ligated, in frame with glutathione S-transferase (GST) cDNA, into pGEX-1n (XhoI/EcoRI). GST and GSTCxCT proteins were isolated from DH5␣ bacteria induced with isopropyl-␤-D-thioglactopyranoside according standard procedures. GFP in pMT2 was obtained from G. Zondag (The Netherlands Cancer Institute).
cDNA Transfection-Cells were transfected with pCDNA3 plasmid encoding Myc-tagged Cx43 and/or versions of c-Src using standard calcium phosphate precipitation. COS cells were transfected by the standard DEAE-dextran transfection method, using 1 g of plasmid DNA per 10 5 cells. Antibodies-Mouse anti-Cx43 and anti-phosphotyrosine (PY20) monoclonal antibodies were from Transduction Laboratories (Lexington, KY). Mouse anti-Myc was applied as culture supernatant from the 9E10 hybridoma (ATCC). Rabbit anti-human c-Src (SRC2) was from Santa Cruz Biotechnology (Santa Cruz, CA), and mouse anti v-Src monoclonal antibody was from Calbiochem. Secondary antibodies (rabbit anti-mouse and swine anti-rabbit) conjugated to horseradish peroxidase were obtained from Dako (Glostrup, Denmark), and antibodies conjungated to Texas Red were from Molecular Probes (Leiden, The Netherlands).
Immunoprecipitation-Cells were lysed in 1% Nonidet P-40, 0.25% sodium deoxycholate lysis buffer as described previously (5) . Lysates were clarified and precipitated with antibody precoupled to protein A-Sepharose Cl-4B (Amersham Pharmacia Biotech, Uppsala, Sweden). Incubation was for 1 h to overnight at 4°C. Precipitates were washed, and proteins were eluted in Laemmli sample buffer (LSB: 50 mM TrisCl, pH 6.8, 2% SDS, 10% glycerol, 5% ␤-mercaptoethanol, 0.1% bromphenol blue).
In Vitro Kinase Assay-Src was expressed in COS-7 cells as described above. Cells were lysed 40 h post-transfection in Triton X-100 buffer (150 mM NaCl, 50 mM Tris-Cl, pH 7.4, 2 mM EGTA, and 0.1% Triton X-100). Src immunoprecipitates were washed in in vitro kinase buffer (IVKB: 1 mM dithiothreitol, 10 mM MgCl 2 , 50 mM Tris-Cl, pH 7.4). Substrate (10 g of GST and GST-Cx43CT) and 0.37 Mbq of [␥-
32 P]ATP (Amersham Pharmacia Biotech) were added in IVKB. Reactions carried out at 30°C were stopped after 1 h with LSB. Samples were subjected to SDS-PAGE and analyzed by autoradiography and immunoblotting.
SDS-PAGE and Immunoblotting-Samples in LSB were boiled for 5 min, subjected to SDS-PAGE (12.5% gel), and transferred to nitrocellulose, as described previously (5) . The blots were blocked and subsequently probed with primary and secondary antibodies. Immunostained proteins were visualized using enhanced chemoluminescence (Amersham Pharmacia Biotech).
Gap Junctional Communication and Immunofluorescence AssaysScrape-loading of lucifer yellow, microinjections, electrophysiological measurements, and immunofluorescence assays were carried out as described previously (5) .
RESULTS AND DISCUSSION
The COOH-terminal Tail of Cx43 Is a Substrate for Activated c-Src in Vitro-Previous studies have shown that Cx43 is tyrosine-phoshorylated by oncogenic v-Src, which correlates with permanent disruption of GJC in v-Src-transformed cells (1, 8 -12) , while endogenous c-Src has been implicated in the transient inhibition of Cx43-based GJC in normal cells (5) . We set out to examine whether c-Src can phosphorylate Cx43 on its COOH-terminal tail in vitro. To this end, we used the Cx43 tail (residues 227-382; Fig. 1 (iii) kinase-dead c-Src (c-SrcK Ϫ , K295M mutation) (Fig. 1,  lower panel) . Src proteins were immunoprecipitated from transfected COS-7 cells and incubated with GST-Cx43CT.
[␥-32 P]ATP was then added for in vitro kinase assays. As shown in Fig. 2 (11) . However, since v-Src and c-Src show differential association to cellular substrates (16, 17) , it remains unclear whether c-Src may act similarly to v-Src in phosphorylating Cx43. To examine the importance of Cx43 residue Tyr 265 in the action of c-Src, we generated mutant versions of Cx43 in which tyrosine residues 265 and 267 were substituted by phenylalanine (Cx43-Y265F and Cx43-Y267F, respectively; Fig. 1, upper panel) . COS-7 cells were transfected with Myctagged Cx43 (wt, Y265F, and Y267F) with or without the various versions of c-Src. Immunoblot analysis of total cell lysates reveals that the three distinct Cx43 proteins are properly expressed to comparable levels (Fig. 3A, middle panels) . No tyrosine phosphorylation of any of the Cx43 proteins is detected in control transfectants, nor in cells expressing kinase-dead c-Src (Fig. 3) . When c-Src or c-SrcK ϩ is cotransfected, however, phosphotyrosine is detected in wt Cx43 and Cx43-Y267F, but not in the Cx43-Y265F mutant (Fig. 3A) . We also analyzed Cx43 immunoprecipitates for the presence of phosphotyrosine. As shown in Fig. 3B , wt Cx43 and mutant Cx43Y267F are tyrosine-phosphorylated in c-Src-overexpressing cells, whereas Cx43Y265F (precipitated at comparable amounts) is not. From these results we conclude that active c-Src phosphorylates Cx43 on residue Tyr 265 and that residue Tyr 267 is not a Src phosphorylation site.
We note that, at least in some experiments, a faint phosphotyrosine signal was still detectable in the Cx43-Y265F mutant (Fig. 3B) . This may represent endogenous Cx43 that is coprecipitated with transfected Myc-tagged Cx43. An alternative or additional possibility is that c-Src may phosphorylate Cx43 on another tyrosine residue with very low stoichiometry. The latter possibility was not investigated in further detail.
Association between Active c-Src and Cx43-We next examined whether c-Src can stably interact with Cx43 in intact cells. COS-7 cells were transfected with Myc-tagged versions of Cx43 (wt, Y265F, and Y267F mutants) together with the various c-Src constructs. We then assayed for the presence of Cx43 in Src precipitates. In SrcK ϩ precipitates, both wt Cx43 and the Cx43-Y267F mutant are readily detected, whereas the Cx43-Y265F mutant is not (Fig. 4, upper right panel) . Fig. 4 further shows that a very weak association is detected between wt Cx43 and wt c-Src and that Cx43 fails to interact with kinasedead c-Src (SrcK Ϫ ). These results emphasize the importance of Cx43 residue Tyr 265 , and they support a model in which phosphorylation of Cx43-Tyr 265 is essential for stable interaction between Cx43 and active c-Src.
Our efforts to detect an interaction between endogenous c-Src and Cx43 in agonist-stimulated Rat-1 cells were not successful. This negative result is not entirely unexpected, how- Cell-to-cell diffusion of LY was measured at 3 min after micro-injection. It is seen that SrcK ϩ expression blocks GJC. Strikingly, communication is restored after coexpression of either COOH-terminally truncated Cx43-⌬263 or Cx43-Y265F, whereas expression of wt Cx43 or Cx43-Y267F fails to bypass SrcK ϩ action. B, quantitation of the LY micro-injection experiments illustrated in A. The degree of intercellular LY diffusion was determined at 3 min after dye injection into GFP-positive cells (as illustrated in A). GJC was scored as either "positive" or "negative." In control cells, 90% of gap junctions are open (left bar). SrcK ϩ expression largely blocks GJC. This effect is rescued by cotransfection of Cx43-Y265F or Cx43-⌬263, but not by wt Cx43 or Cx43-Y267F. That rescue is not 100% complete may be due to less than 100% triple-transfection efficiency per cell. C, expression and localization of Cx43 in SrcK ϩ -transfected Rat-1 cells. Rat-1 cells were transiently transfected with the indicated Cx43 and SrcK ϩ constructs, using the same procedures as in A. GFP was cotransfected to identify transfected cells. Cells were stained for Cx43-Myc, using 9E10 anti-Myc and Texas Red-conjugated goat-anti-mouse antibodies. It is seen that transfected Cx43-Myc is located both at the cell periphery and in intracellular vesicles. Bar: 20 m.
ever, given that: (i) agonist-induced c-Src activation and disruption of GJC are transient events (5, 18, 19) ; (ii) c-Src and Cx43 are expressed at relatively low levels in normal fibroblasts; and (iii) the high stringency lysis conditions required to solubilize Cx43 from junctional plaques is likely to disrupt protein-protein interactions, particularly when such interactions are labile and of transient nature. (Fig. 5B) . Cotransfection of wt Cx43 does not restore normal communication, nor does expression of Cx43-Y267F, which both serve as Src substrates (Fig. 5A, middle left) . Strikingly, when the Src phosphorylation site Tyr 265 in Cx43 is removed either by point mutation (Cx43Y265F) or by COOH-terminal tail truncation (Cx43⌬63), gap junctional communication is restored (Fig. 5, A and B) . Immunofluorescence analysis of transfected cells did not reveal gross differences in expression levels of the Cx43 mutants (Fig.  5C ), although we cannot rule out the formal possibility that activated Src may somehow affect Cx43 localization and/or gap junction assembly. Nevertheless, our results suggest that cSrc-mediated phosphorylation of Cx43 on residue Tyr 265 is a key event in closure of Cx43-based gap junctions.
Cx43-Y265F Rescues the Communication-defective Phenotype in SrcK
Our findings support a model in which G protein-coupled receptor agonists, such as LPA, endothelin, and thrombin, transiently disrupt GJC through a pathway that involves c-Srcmediated phoshorylation of Cx43 residue Tyr 265 as a critical step (5) . In an attempt to test this model directly, we stably expressed either wt Cx43 or mutant Cx43-Y265F in communication-defective A431 and HeLa carcinoma cells, and subsequently examined GJC in response to LPA and other growth factors. Unexpectedly, however, while expression of wt Cx43 or Cx43-Y265F did confer GJC to these cells (as determined by dye diffusion and electrophysiological measurements), coupling in the transfectants could not be inhibited by LPA, thrombin, epidermal growth factor, or phorbol ester.
2 It thus appears that, although transfected Cx43 does restore GJC, its regulation by extracellular agonists is impaired, as if an essential signaling component or Cx43-interacting partner is lacking or nonfunctional in the Cx43 transfectants.
Concluding 13 for a model in which the Cx43-Tyr 265 has no major role). Yet, it should be noted that there are various important differences between v-Src and c-Src. Not only is v-Src constitutively active because it lacks the auto-inhibitory Tyr 527 residue, c-Src and v-Src also show differential association to cellular substrates (16, 17) . Of particular relevance is the finding that the isolated SH3 domain of v-Src binds to proline-rich motifs in Cx43 in vitro, whereas the c-Src SH3 domain mediates only weak binding to Cx43 under the same conditions (11) . Hence, it will be very difficult to detect a pre-existing SH3-mediated association between endogenous c-Src and Cx43 in vivo. Although tyrosine phoshorylation of Cx43 could not be detected in Rat-1 cells following receptor stimulation (for likely reasons outlined above), a recent study showed tyrosine phosphorylation of Cx43 in cardiomyopathic heart tissue (20) . This correlated with increased c-Src activity and decreased GJC (20) , consistent with a model in which active c-Src interacts with Cx43 and thereby mediates inhibition of GJC.
In conclusion, our results provide further evidence for the direct involvement of c-Src in inhibiting Cx43-based GJC following stimulation of G protein-coupled receptors (5), and they emphasize the importance of residue Tyr 265 as a c-Src target in this process. Obviously, a full understanding of how Cx43-based GJC is regulated by physiological and/or pathophysiological stimuli can only be obtained if all Cx43-interacting partners are known. In addition to c-Src, we have identified the ZO-1 protein as an interacting partner of the Cx43 COOH-terminal tail (a PDZ-domain interaction; Ref. 15) . One challenge for future studies is to elucidate if and how c-Src and ZO-1 may interact to regulate the function of the Cx43 multiprotein complex and channel gating. Future studies should also elucidate the G protein-effector pathway that is responsible for Src-dependent inhibition of Cx43-based GJC in normal cells.
